Ely Benaim

Ely Benaim, M.D., is the Chief Medical Officer and Executive Vice President of Development at SonALAsense, a position he has held since April 2023. In this role, he is pivotal in advancing the company's non-invasive Sonodynamic Therapy (SDT) aimed at treating aggressive brain tumors, particularly diffuse intrinsic pontine glioma (DIPG) .12

Professional Background

Dr. Benaim has over two decades of experience in the medical field, primarily focusing on oncology. Before joining SonALAsense, he served as the Chief Medical Officer at Novocure from April 2019 to January 2023 and held similar roles at Rexahn Pharmaceuticals and BERG Health .23 His earlier positions include significant roles at Millennium Pharmaceuticals and Sangamo BioSciences, among others .2

Education

Dr. Benaim received his medical degree from Universidad Central de Venezuela in 1987. He completed a Pediatric Residency at the University of South Florida (1990-1993) and further specialized in Hematology/Oncology as a Post-Doctoral Research Associate at the University of Tennessee-Health Science Center (1993-1996). He also completed a fellowship in Bone Marrow Transplantation at St. Jude Children's Research Hospital (1996-1997) .23

Contributions

At SonALAsense, Dr. Benaim's expertise is crucial for obtaining FDA approval for new therapies and facilitating their commercialization .1 His extensive background in pediatric oncology and clinical research positions him as a valuable asset in the fight against challenging cancers.